Netflix Stock Price Soars After Earnings Report Record New Memberships
Netflix stock price ( NASDAQ: NFLX ) is up more than 13% in the after-hours following its release of the fourth-quarter earnings report for fiscal year 2024. The streaming company recorded a 16% increase in revenue year-over-year, reaching 19% on a foreign exchange (F/X) neutral basis, which the
If you invested $1000 in Chipotle Mexican Grill (NYSE:CMG) 5 years ago, here's how much it's worth today
They say, “If it looks like a restaurant, cooks food like a restaurant, and serves food like a restaurant, then it’s probably a restaurant.”. However, this might not be how investors see Chipotle Mexican Grill ( NYSE:CMG ). Chipotle’s stock is currently trading at a P/E ratio of around 54, while many
Sigma Lithium Announces 2025 Full Year Earnings Presentation Call on March 30 at 7:30 AM EST
Newsfile
3 hours ago
SUMMARYEvent Title: Sigma Lithium Fourth Quarter 2025 Earnings Results CallEvent Date: March 30, 2026Start Time: 7:30 a.m. ESTAttendee URL: https://mzgroup.zoom.us/webinar/register/WN_-yfOrvFmTCqtQXGv6fVr5gSão Paulo, Brazil--(Newsfile Corp. - March 2
Skychain Technologies Inc. Provides Update on Financial Position, Asset Status, and Ongoing Transition Issues
Newsfile
21 hours ago
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2026) - Skychain Technologies Inc. (TSXV: SCT.H) (the "Company" or "Skychain") provides a further update regarding its financial position, asset status, and the ongoing transition to the board
New $150,000 Audiophile System by Future Audiophile Helps Harvard Students Creatively Deal with Stress and Anxiety Through Audiophile Sound
Newsfile
22 hours ago
FutureAudiophile.com has donated a sound system to Harvard's Shelemay Audio Lab offering a drug-free, measurable way for students to creatively lower stress levels.Los Angeles, California--(Newsfile Corp. - March 28, 2026) - Thanks to the magazine an
Dermatology Online Discussion Forum Named Top Forum for 2026
Newsfile
22 hours ago
The Dermatology Online Discussion Forum was recognized as a top dermatology discussion forum for dermatologists in 2026, highlighting its role in fostering timely, peer-driven collaboration and advancing global professional engagement in dermatologyD
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
GlobeNewswire Inc.
Yesterday at 7:00 PM GMT
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skinFollowing positive Phase 2 LI
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
GlobeNewswire Inc.
Yesterday at 7:00 PM GMT
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositisBrepocitinib 30 mg was superior to placebo on the primary an
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
GlobeNewswire Inc.
Yesterday at 5:30 PM GMT
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, an
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
GlobeNewswire Inc.
Yesterday at 3:00 PM GMT
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants ag
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
GlobeNewswire Inc.
Yesterday at 3:00 PM GMT
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-20
Searchless.ai Launches as the First Publication Dedicated to Covering the End of Traditional Search
Newsfile
Yesterday at 10:47 AM GMT
New daily intelligence publication tracks the shift from Google to AI-powered discovery as 56% of searches now end without a clickRome, Italy--(Newsfile Corp. - March 28, 2026) - Searchless.ai has launched as a new publication focused on exclusively
